



Testimony by Eric Gally on behalf of Indivior, Inc.
in support of HB 572

- 20 states have standing orders that include nalmafene either by name or through language that includes all FDA-approved products.
- In addition to the 20 states with updated standing orders, there are 13 states that are “entity specific.” The two categories amount to 33 states where Opvee “is not blocked”
- In other states, like MD, there are statewide standing orders specific to naloxone. In these jurisdictions, entities rely on the statewide standing order and it’s very challenging to find a practitioner who is willing to put their license on the line to sign a local standing order if it is not supported at the state level – there’s a perceived increased risk
- The American Medical Association included in their December Overdose Report ([Pg. 13](#)) included the following recommendation: “Ensure OTC naloxone is available and **update standing orders for pharmacies to include naloxone and all other FDA-approved opioid-overdose reversal medications.**”

Updated standing order (20)

- AK, AL, AR, AZ, GA, IL, IN, KS, KY, LA, MS, MN, NC, NH, NJ, NM, OH, UT, VA, WV

Entity Specific (13)

- CT, DC, HI, ID, ME, MN, ND, NV, RI, SC, TN, TX, WY